To order Tagrisso from Germany please contact us by e-mail email@example.com
Tagrisso information, buy
Tagrisso 80 mg — 8500 EUR
Tagrisso 40 mg — 8500 EUR
We deliver all over the world. The drug buy in pharmacies in Germany
What is Tagrisso?
Tagrisso (osimertinib) is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Tagrisso is used to treat a certain type of non-small cell lung cancer. This medicine is used only if your tumor has a specific genetic marker, for which your doctor will test.
Tagrisso is usually given after other cancer medicines have been tried without success.
Tagrisso was approved by the US Food and Drug Administration (FDA) on an «accelerated» basis. In clinical studies, tumors responded to this medicine. However, further studies are needed to determine if this medicine can lengthen survival time.
Osimertinib may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your doctor right away if you have any new or worsening lung symptoms, including trouble breathing, shortness of breath, cough, or fever.
Osimertinib may cause heart problems that may lead to death. Your doctor should check your heart function before you start taking Tagrisso and during treatment. Call your doctor right away if you have any of the following signs and symptoms of a heart problem: feeling like your heart is pounding or racing, shortness of breath, swelling of your ankles and feet, feeling lightheaded.
Before taking this medicine
You should not use Tagrisso if you are allergic to osimertinib.
To make sure Tagrisso is safe for you, tell your doctor if you have:
- a breathing disorder;
- an electrolyte imbalance (such as high or low levels of calcium, potassium, or magnesium in your blood);
- a heart rhythm disorder; or
- a personal or family history of long QT syndrome.
Osimertinib can harm an unborn baby or cause birth defects. Do not use if you are pregnant, and tell your doctor right away if you become pregnant. Use effective birth control while you are using this medicine and for at least 6 weeks after your last dose.
It is not known whether osimertinib passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine and for at least 2 weeks after your last dose.
If a man fathers a baby while using Tagrisso, the baby may have birth defects. Use a condom to prevent pregnancy during your treatment, and for at least 4 months after your treatment ends.
This medicine may affect fertility (your ability to have children), whether you are a man or a woman. However, you should use birth control as recommended during and after treatment with Tagrisso.